Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmunity in kidney diseases.

Ralph Kettritz1

  • 1Medical Faculty of the Charite, Experimental and Clinical Research Center, Franz-Volhard Clinic at the Max-Delbruck Center, HELIOS Klinikum Berlin, Germany. kettritz@charite.de

Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum
|August 21, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Similar and yet not quite the same: unmasking distinct type I interferon signatures in ANCA vasculitis.

Kidney international·2026
Same author

[KDIGO-Update: Treatment of ANCA vasculitis].

Deutsche medizinische Wochenschrift (1946)·2025
Same author

[Diagnostics and treatment of gout : Short version of the German S3 guideline].

Zeitschrift fur Rheumatologie·2025
Same author

[Diagnostics and treatment of gout : S3 guideline of the German Society for Rheumatology and Clinical Immunology (DGRh, lead management) and participating professional societies: German Society for Internal Medicine (DGIM), German Society for General Medicine and Family Medicine (DEGAM), German Society for Nephrology (DGfN), German Society for Orthopaedic and Trauma Surgery (DGOU), German Society for Nutritional Medicine (DGEM), German Roentgen Society-Society for Medical Radiology (DRG), German Rheumatism League].

Zeitschrift fur Rheumatologie·2025
Same author

CRISPR-Cas9 mediated proteinase 3 autoantigen deletion as a treatment strategy for anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Kidney international·2025
Same author

Endothelial but not systemic ferroptosis inhibition protects from antineutrophil cytoplasmic antibody-induced crescentic glomerulonephritis.

Kidney international·2025
Same journal

Standardization of tumor markers - priorities identified through external quality assessment.

Scandinavian journal of clinical and laboratory investigation. Supplementum·2016
Same journal

Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.

Scandinavian journal of clinical and laboratory investigation. Supplementum·2016
Same journal

microRNAs as cancer biomarkers.

Scandinavian journal of clinical and laboratory investigation. Supplementum·2016
Same journal

Biomarkers along the continuum of care in lung cancer.

Scandinavian journal of clinical and laboratory investigation. Supplementum·2016
Same journal

Precision medicine: what's all the fuss about?

Scandinavian journal of clinical and laboratory investigation. Supplementum·2016
Same journal

Serum thyroglobulin in the monitoring of differentiated thyroid cancer.

Scandinavian journal of clinical and laboratory investigation. Supplementum·2016
See all related articles

Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is a leading cause of rapidly progressive kidney disease. Novel research highlights membrane-PR3 expression on neutrophils as a potential biomarker for targeted therapies.

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Autoimmune processes can damage glomerular, tubular, and vascular kidney structures.
  • Rapidly progressive glomerulonephritis (GN), often with extra-renal involvement, presents dramatically and life-threateningly.
  • Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, anti-glomerular basement membrane (anti-GBM) GN, and lupus nephritis are key examples.

Purpose of the Study:

  • To focus on ANCA-associated GN as the primary cause of rapidly progressive GN.
  • To explore the diagnostic and causal role of ANCA in disease development.
  • To investigate the clinical significance of membrane-proteinase 3 (PR3) expression on neutrophils as a novel biomarker.

Main Methods:

  • Review of ANCA-associated diseases including Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome.

Related Experiment Videos

  • Analysis of in vitro and in vivo findings establishing the causal role of ANCA.
  • Investigation of membrane-PR3 expression patterns and their association with neutrophil subsets.

    • Main Results:

    • ANCA-associated GN is identified as the leading cause of rapidly progressive GN.
    • ANCA serves as a valuable diagnostic tool due to its strong association with relevant diseases.
    • Membrane-PR3 expression on neutrophils is clinically significant, indicating a potential novel biomarker.

    Conclusions:

    • Understanding the interaction between PR3 and the NB1 receptor (CD177) on neutrophils may lead to more selective therapeutic agents.
    • Membrane-PR3 expression is restricted to a stable neutrophil subset defined by the NB1 receptor.
    • Further research into the PR3-NB1 interaction holds promise for developing targeted treatments for ANCA-associated kidney diseases.